News on Hepatitis continually updated from thousands of sources around the net.
Trending on the Topix Network
PrEP researchers Walid Heneine, Gerardo Garcia-Lerma, Peter Anton, and Craig Hendrix during a 2011 CROI panel HIV researchers from across the globe came together in Boston last week from March 3-6 for the annual Conference on Retroviruses and Opportunistic Infections .
A: Many things can be done to help ensure a traveler's health and safety. See your healthcare provider well before your planned departure date.
Variable responses to the Hepatitis B Virus vaccine have recently been reported as strongly dependent on genetic causes.
A new combination of drugs offers a cure for hepatitis C, the virus that often leads to liver disease.
This easily beats the S&P's return of 1.5% over the same time period. However, can Merck keep the bull run going? Merck released details this week of a phase 2 trial involving a combination of Merck's MK-5172 and MK-8742 to treat patients co-infected with HIV and hepatitis C. The administration of the combination for 12 weeks resulted in robust ... (more)
Physical inactivit... )--GreenHunter Resources, Inc. , announced today that it has declared a monthly cash dividend on the Company's 10.... )--Research and Markets has announced the addition of the "Global Unsaturated Polyester Resin --BRTRC Federal Solutions, a leading mid-sized firm focused on providing integrated technical solutions to the ... (more)
After years of running Minnesota's largest needle exchange, Brian Warden is beginning to see something new among the increasing numbers of suburban and rural heroin users coming to trade in used needles.
Martin Khor, executive director of the South Centre, warns that negotiations on the Trans Pacific Partnership Agreement are a matter of life and death.
Conatus Pharmaceuticals Inc. has announced the initiation of a Phase 2 clinical trial of its lead drug emricasan for the treatment of patients with chronic liver disease and acute exacerbations of chronic liver disease, including acute-on-chronic liver failure, chronic liver failure, Non-alcoholic fatty liver disease and non-alcoholic ... (more)
Promising preliminary results from a trial of Merck's MK-5172 and MK-8742, given with or without ribavirin, showed that the combination therapy was as safe in treating genotype 1 of hepatitis C virus among those coinfected with HIV as it was among those monoinfected with hep C. The treatment appears to boast near-perfect success rates.
One of the hottest research fields in biotech is for a disease most people have never heard of.
The big question is whether Gilead can keep the momentum going. Its all-oral cocktail that includes Sovaldi is under review at the Food and Drug Administration, which should make it more appealing than the current regimen that requires many patients to also inject peginterferon, which has nasty side effects.
At least one percent of Americans are chronically infected with the hepatitis C virus, which over time can severely damage the liver, according to a new study.
The company won approval from Hong Kong regulators to start a phase 2a trial for its ARC-520 drug for hepatitis B. ARC-520 will be dosed alongside Bristol-Myers ' Hepatitis B drug Baraclude, a therapy that generates more than a billion in annual sales for Bristol.
Treatment options of Hepatitis C have been limited. Sometimes the available treatments have more severe side effects than those caused by the actual illness.